Approaches to Short-Acting Neuromuscular Blocking Agents

  • J. B. Stenlake
Conference paper


After almost fifty years suxamethonium is still widely used for a variety of short operations where rapid onset and short action are advantageous [1]. Its drawbacks are well known and widely understood but it has long been recognised that a competitive agent with rapid onset and short action would be preferable. However, the rational design of any such agent depends on an ability to correlate these effects with particular aspects of chemical structure in a way that does not detract from the other essential requirements of a safe and effective neuromuscular blocking agent.


Neuromuscular Blocking Neuromuscular Blocking Agent Neuromuscular Blocking Effect Vagal Blockade Competitive Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Norman J. Neuromuscular blocking agents of the future. In: Bowman WC, Denissen PAF, Feldman F, eds. Neuromuscular blocking agents: past, present and future. Proceedings of the David Savage Memorial Interface Symposium, London 1990. Amsterdam: Excerpta Medica, 1990; 15–19.Google Scholar
  2. 2.
    Bowman WC, Rodger IW, Houston J, Marshall RJ, Mclndewar I. Structure: act ion relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthet ised cat. Anesthesiology 1988 ; 69: 57–62.PubMedCrossRefGoogle Scholar
  3. 3.
    Hughes R, Payne JP. Clinical assessment of atracurium using the single twitch and tetanic responses of the adductor policis muscle. Br. J.Anaesth. 1983 ; 55: 47S–52S.Google Scholar
  4. 4.
    Muir AW, Marshall RJ. Comparat ive neuromuscular blocking effects of vecuronium, pancuronium, Org 6368 and suxamethonium in the anaesthetised domestic pig. Br. J.Anaesth. 1987 ; 59: 622–629.PubMedCrossRefGoogle Scholar
  5. 5.
    Savarese JJ. The clinical pharmacology of mivacurium. In: Bowman WC, Denissen PAF, Feldman F. eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica, 1990; 69–78.Google Scholar
  6. 6.
    Stenlake JB, Waigh RD, Dewar GH, Hughes R. Chapple DJ, Coker GG. Biodegradable neuromuscular blocking agents. Part 4. Atracurium besylate and related polyalkylene di-esters) Eur J Med Chem 1981 ; 16: 515–524.Google Scholar
  7. 7.
    Stenlake JB, Hughes R. In vitro degradation of atracurium in human plasma. Br J Anaesth 1987; 59: 806–810.PubMedCrossRefGoogle Scholar
  8. 8.
    Stenlake JB, Dhar NC. Haddow J, McDonald IM, Maehr RB, Wastila WB. Neuromuscular blocking agents. Some approaches to short acting compounds. Eur J Med Chem 1992; 27: 463–477.CrossRefGoogle Scholar
  9. 9.
    Albert, A. Heterocyclic Chemistry. London: Athlone Press, 1959; 223–224.Google Scholar
  10. 10.
    Iacono JM, Johnson BC. Thiamine metabolism 1. The metabolism of thiazole-2-[C] 14[D]C-thiamine in the rat. J Am Chem Soc 1957 ; 79: 6321–6324.CrossRefGoogle Scholar
  11. 11.
    Amoswh, Neal A. Isolation and identificat ion of 3 (2-methyl-4-amino-5-pyrimidylmethyl)-4-methyl thiazole-5-acetic acid (thiamine acetic acid) and 2-methyl-4-amino-5-formylaminomethylpyrimidine as metabolites of thiamine in the rat. J Biol Chem 1970; 245: 5643–5648Google Scholar
  12. 12.
    Stenlake JB. Dhar NC. Henderson CF. Maehr RB, Scharver J. Wastila WB. Midgley JM. Neuromuscular blocking agents. Approaches to short acting compounds 2. Bis-thiazolium salts. Eur J Med Chem 1993 ; 28: 415–418CrossRefGoogle Scholar
  13. 13.
    Kharkevich DA, Skoldinev AP, Lemina EY, Igumnova ND. Re lat ions between structure, hydrolysis rate and activity of dicarboxylic esters. Farmakol Toxicol (Moscow) 1989: 52: 34–37(C.A. 110: 205078t)Google Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • J. B. Stenlake
    • 1
  1. 1.Department of Pharmaceutical SciencesUniversity of StrathclydeGlasgowUK

Personalised recommendations